

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
27 August 2020 (27.08.2020)



(10) International Publication Number
WO 2020/172002 A1

(51) International Patent Classification:

C07K 14/54 (2006.01) C07K 16/46 (2006.01)
C07K 16/24 (2006.01) A61K 9/08 (2006.01)
A61K 39/395 (2006.01) A61K 38/19 (2006.01)
C07K 16/28 (2006.01) A61K 38/20 (2006.01)

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))

(21) International Application Number:

PCT/US2020/017594

Published:

- with international search report (Art. 21(3))
- with sequence listing part of description (Rule 5.2(a))

(22) International Filing Date:

11 February 2020 (11.02.2020)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/807,006 18 February 2019 (18.02.2019) US
62/880,846 31 July 2019 (31.07.2019) US
62/947,198 12 December 2019 (12.12.2019) US

(71) Applicant: **ELI LILLY AND COMPANY** [US/US]; Lilly Corporate Center, Indianapolis, Indiana 46285 (US).

(72) Inventors: **CORVARI, Vincent John**; c/o Eli Lilly And Company, P.O. Box 6288, Indianapolis, Indiana 46206-6288 (US). **PISUPATI, Karthik**; c/o Eli Lilly And Company, P.O. Box 6288, Indianapolis, Indiana 46206-6288 (US). **SHI, Galen Huaiqiu**; c/o Eli Lilly And Company, P.O. Box 6288, Indianapolis, Indiana 46206-6288 (US).

(74) Agent: **MARKS, Duane C.** et al.; Eli Lilly And Company, P.O. Box 6288, Indianapolis, Indiana 46206-6288 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(54) Title: THERAPEUTIC ANTIBODY FORMULATION

(57) Abstract: Stable aqueous pharmaceutical formulations for therapeutic antibodies and methods of using such stable aqueous pharmaceutical formulations.

WO 2020/172002 A1